-
Product Insights
NewPheochromocytoma – Drugs In Development, 2024
Empower your strategies with our Pheochromocytoma – Drugs In Development, 2024 report and make more profitable business decisions. Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops from cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath, and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL), and neurofibromatosis 1 (NF1). The Pheochromocytoma drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewNeurofibromatoses – Drugs In Development, 2024
Empower your strategies with our Neurofibromatoses – Drugs In Development, 2024 report and make more profitable business decisions. Neurofibromatosis (NF) is a term for a group of genetic disorders that cause benign tumors to grow on nerve tissue. There are three types of NF: NF1, NF2, and schwannomatosis. Each type has different signs and symptoms, such as skin spots, freckles, bumps, hearing loss, vision loss, pain, and bone deformities. NF is caused by mutations in certain genes that regulate nerve cell...
-
Product Insights
NewNeurofibromatoses Type I (Von Recklinghausen’s Disease) – Drugs In Development, 2024
Empower your strategies with our Neurofibromatoses Type I (Von Recklinghausen's Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules, and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy,...
-
Product Insights
NewNeuroendocrine Carcinoma – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Neuroendocrine carcinoma (NEC) is a rare type of cancer that arises from neuroendocrine cells, which are cells that have both nerve and hormone functions. NEC can occur in various organs, such as the lungs, pancreas, stomach, intestines, appendix, rectum, breast, kidney, ovaries, or testicles. NEC can be classified into well-differentiated or poorly differentiated tumors, depending on how they look under the microscope...
-
Product Insights
NewAdrenal Gland Cancer – Drugs In Development, 2024
Empower your strategies with our Adrenal Gland Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Adrenal gland cancer is a rare type of neuroendocrine tumor that originates from the cells of the adrenal glands, which are located on top of the kidneys. The adrenal glands produce hormones that regulate various functions in the body, such as blood pressure, metabolism, stress response, and sex drive. Adrenal gland cancer can affect the production of these hormones, causing symptoms...
-
Product Insights
NewPeripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Drugs In Development, 2024
Empower your strategies with our Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Drugs In Development, 2024 report and make more profitable business decisions. Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas that originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include a lump or swelling in the in the soft tissue, numbness, burning, tingling or pins and needles, weakness of the affected muscles, and dizziness or loss of balance....
-
Product Insights
NewMycosis Fungoides – Drugs In Development, 2024
Empower your strategies with our Mycosis Fungoides – Drugs In Development, 2024 report and make more profitable business decisions. Mycosis fungoides is a rare type of non-Hodgkin lymphoma, specifically a subtype of cutaneous T-cell lymphoma (CTCL), which primarily affects the skin. It is characterized by the abnormal accumulation of malignant T-cells (a type of white blood cell) in the skin, leading to various skin symptoms and, in advanced stages, potential involvement of other organs. Mycosis fungoides is the most common type...
-
Product Insights
NewMedulloblastoma – Drugs In Development, 2024
Empower your strategies with our Medulloblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occurs in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting, and difficulty with walking and balance. Medulloblastoma can spread to...
-
Product Insights
NewAdenocarcinoma – Drugs In Development, 2024
Empower your strategies with our Adenocarcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Adenocarcinoma is a type of cancer that starts in mucus-producing (glandular) cells. Many organs have these types of cells and adenocarcinoma can develop in any of these organs. The symptoms of adenocarcinoma will depend on which organ is affected by cancer. The patients may not experience any symptoms until the cancer is more advanced. The Adenocarcinoma drugs in development market research report provide...
-
Product Insights
NewNeuroendocrine Tumors – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Tumors – Drugs In Development, 2024 report and make more profitable business decisions. Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptoms include hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. Treatments include surgery, radiation therapy, and...